nach oben

Die Innere Medizin

Erschienen in:

06.07.2018 | Pankreaskarzinom | CME

Duktales Adenokarzinom des Pankreas

verfasst von: Prof. Dr. E. Gallmeier, T. M. Gress

Erschienen in: Die Innere Medizin | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das duktale Adenokarzinom ist die häufigste maligne Raumforderung des Pankreas. Trotz großer Forschungsanstrengungen und gradueller Verbesserungen der Diagnostik und Therapie weist es immer noch eine sehr ungünstige Prognose auf. Dieser CME-Fortbildungsbeitrag liefert unter Berücksichtigung der aktuellen deutschen, europäischen und US-amerikanischen Leitlinien einen allgemeinen Überblick zu dieser Erkrankung. Zudem werden ausgewählte aktuelle Aspekte der Epidemiologie, Pathogenese und Genetik sowie Grundprinzipien der Diagnostik und Therapie einschließlich potenzieller zukünftiger Therapieoptionen erörtert.

Fitzgerald TL, Hickner ZJ, Schmitz M et al (2008) Changing incidence of pancreatic neoplasms: a 16-year review of statewide tumor registry. Pancreas 37:134–138CrossRefPubMed

Bosman FT, Carneiro F, Hruban RH et al (2010) WHO classification of tumours of the digestive system, 4. Aufl. World Health Organization (WHO), International Agency for Research on Cancer (IARC), Lyon

Malvezzi M, Carioli G, Bertuccio P et al (2018) European cancer mortality predictions for the year 2018 with focus on colorectal cancer. Ann Oncol. https://doi.org/10.1093/annonc/mdy033 PubMedCrossRef

Rahib L, Smith BD, Aizenberg R et al (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74:2913–2921CrossRefPubMed

Siegel RL, Miller KD, Jemal A (2017) Cancer Statistics, 2017. CA Cancer J Clin 67:7–30CrossRefPubMed

Neoptolemos JP, Palmer DH, Ghaneh P et al (2017) Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389:1011–1024CrossRefPubMed

Von Hoff DD, Ervin T, Arena FP et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703CrossRef

Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825CrossRefPubMed

Oettle H, Neuhaus P, Hochhaus A et al (2013) Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 310:1473–1481CrossRefPubMed

10.

Bailey P, Chang DK, Nones K et al (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531:47–52CrossRefPubMed

11.

Cancer Genome Atlas Research Network Electronic address aadhe, cancer genome atlas research N (2017) integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32:185–203.e13CrossRef

12.

Jones S, Zhang X, Parsons DW et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–1806CrossRefPubMedPubMedCentral

13.

Waddell N, Pajic M, Patch AM et al (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518:495–501CrossRefPubMedPubMedCentral

14.

Witkiewicz AK, McMillan EA, Balaji U et al (2015) Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun 6:6744CrossRefPubMedPubMedCentral

15.

Roberts NJ, Norris AL, Petersen GM et al (2016) Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discov 6:166–175CrossRefPubMed

16.

Petersen GM (2016) Familial pancreatic cancer. Semin Oncol 43:548–553CrossRefPubMedPubMedCentral

17.

Bartsch DK, Slater EP, Carrato A et al (2016) Refinement of screening for familial pancreatic cancer. Gut 65:1314–1321CrossRefPubMed

18.

Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362:1605–1617CrossRefPubMed

19.

Korc M, Jeon CY, Edderkaoui M et al (2017) Tobacco and alcohol as risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 31:529–536CrossRefPubMed

20.

Ducreux M, Cuhna AS, Caramella C et al (2015) Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v56–v68CrossRefPubMed

21.

Maisonneuve P, Lowenfels AB (2015) Risk factors for pancreatic cancer: a summary review of meta-analytical studies. Int J Epidemiol 44:186–198CrossRefPubMed

22.

Hruban RH, Goggins M, Parsons J et al (2000) Progression model for pancreatic cancer. Clin Cancer Res 6:2969–2972PubMed

23.

Vogelstein B, Fearon ER, Hamilton SR et al (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525–532CrossRefPubMed

24.

Yachida S, Iacobuzio-Donahue CA (2013) Evolution and dynamics of pancreatic cancer progression. Oncogene 32:5253–5260CrossRefPubMed

25.

Basturk O, Hong SM, Wood LD et al (2015) A revised classification system and recommendations from the baltimore consensus meeting for neoplastic precursor lesions in the pancreas. Am J Surg Pathol 39:1730–1741CrossRefPubMedPubMedCentral

26.

Brierley J, Gospodarowicz MK, Wittekind C (2017) TNM classification of malignant tumours. John Wiley & Sons, Chichester, Hoboken

27.

Porta M, Fabregat X, Malats N et al (2005) Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol 7:189–197CrossRefPubMed

28.

Mujica VR, Barkin JS, Go VL (2000) Acute pancreatitis secondary to pancreatic carcinoma. Study Group Participants. Pancreas 21:329–332CrossRefPubMed

29.

Chari ST, Leibson CL, Rabe KG et al (2005) Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 129:504–511CrossRefPubMedPubMedCentral

30.

Seufferlein T, Porzner M, Becker T et al (2013) S3-guideline exocrine pancreatic cancer. Z Gastroenterol 51:1395–1440CrossRefPubMed

31.

Duffy MJ, Sturgeon C, Lamerz R et al (2010) Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol 21:441–447CrossRefPubMed

32.

Ballehaninna UK, Chamberlain RS (2012) The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol 3:105–119PubMedPubMedCentral

33.

Kim JE, Lee KT, Lee JK et al (2004) Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 19:182–186CrossRefPubMed

34.

Al-Hawary MM, Francis IR, Chari ST et al (2014) Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the american pancreatic association. Gastroenterology 146:291–304.e1CrossRefPubMed

35.

Bipat S, Phoa SS, van Delden OM et al (2005) Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis. J Comput Assist Tomogr 29:438–445CrossRefPubMed

36.

Nawaz H, Fan CY, Kloke J et al (2013) Performance characteristics of endoscopic ultrasound in the staging of pancreatic cancer: a meta-analysis. JOP 14:484–497PubMedPubMedCentral

37.

Okasha HH, Naga MI, Esmat S et al (2013) Endoscopic ultrasound-guided fine needle aspiration versus percutaneous ultrasound-guided fine needle aspiration in diagnosis of focal pancreatic masses. Endosc Ultrasound 2:190–193CrossRefPubMedPubMedCentral

38.

Micames C, Jowell PS, White R et al (2003) Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest Endosc 58:690–695CrossRefPubMed

39.

Tempero MA, Malafa MP, Al-Hawary M et al (2017) Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 15:1028–1061CrossRefPubMed

40.

Barreto SG, Windsor JA (2016) Justifying vein resection with pancreatoduodenectomy. Lancet Oncol 17:e118–e124CrossRefPubMed

41.

Evans DB, George B, Tsai S (2015) Non-metastatic pancreatic cancer: resectable, borderline resectable, and locally advanced-definitions of increasing importance for the optimal delivery of Multimodality therapy. Ann Surg Oncol 22:3409–3413CrossRefPubMed

42.

Lutz MP, Zalcberg JR, Ducreux M et al (2017) 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Eur J Cancer 79:41–49CrossRefPubMed

43.

Finks JF, Osborne NH, Birkmeyer JD (2011) Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med 364:2128–2137CrossRefPubMedPubMedCentral

44.

Reames BN, Ghaferi AA, Birkmeyer JD et al (2014) Hospital volume and operative mortality in the modern era. Ann Surg 260:244–251CrossRefPubMedPubMedCentral

45.

Neoptolemos JP, Dunn JA, Stocken DD et al (2001) Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358:1576–1585CrossRefPubMed

46.

Neoptolemos JP, Stocken DD, Bassi C et al (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304:1073–1081CrossRefPubMed

47.

Oettle H, Post S, Neuhaus P et al (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267–277CrossRefPubMed

48.

Nagrial AM, Chang DK, Nguyen NQ et al (2014) Adjuvant chemotherapy in elderly patients with pancreatic cancer. Br J Cancer 110:313–319CrossRefPubMed

49.

Valle JW, Palmer D, Jackson R et al (2014) Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol 32:504–512CrossRefPubMed

50.

Tol JA, Gouma DJ, Bassi C et al (2014) Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery 156:591–600CrossRefPubMed

51.

Hartwig W, Hackert T, Hinz U et al (2011) Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg 254:311–319CrossRefPubMed

52.

Kim KS, Kwon J, Kim K et al (2017) Impact of resection margin distance on survival of pancreatic cancer: a systematic review and meta-analysis. Cancer Res Treat 49:824–833CrossRefPubMed

53.

van der Gaag NA, Rauws EA, van Eijck CH et al (2010) Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 362:129–137CrossRefPubMed

54.

Tol JA, van Hooft JE, Timmer R et al (2016) Metal or plastic stents for preoperative biliary drainage in resectable pancreatic cancer. Gut 65:1981–1987CrossRefPubMed

55.

Ettrich TJ, Schulte LA, Eitel N et al (2017) Surveillance after resection of pancreatic ductal adenocarcinoma with curative intent—a multicenter survey in Germany and review of the literature. Z Gastroenterol 55:657–666CrossRefPubMed

56.

Gillen S, Schuster T, Meyer Zum Buschenfelde C et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. Plos Med 7:e1000267CrossRefPubMedPubMedCentral

57.

Balaban EP, Mangu PB, Khorana AA et al (2016) Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 34:2654–2668CrossRefPubMed

58.

Rombouts SJ, Walma MS, Vogel JA et al (2016) Systematic review of resection rates and clinical outcomes after FOLFIRINOX-based treatment in patients with locally advanced pancreatic cancer. Ann Surg Oncol 23:4352–4360CrossRefPubMedPubMedCentral

59.

Wagner M, Antunes C, Pietrasz D et al (2017) CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Eur Radiol 27:3104–3116CrossRefPubMed

60.

Hurt CN, Mukherjee S, Bridgewater J et al (2015) Health-related quality of life in SCALOP, a randomized phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 93:810–818CrossRefPubMedPubMedCentral

61.

Mukherjee S, Hurt CN, Bridgewater J et al (2013) Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol 14:317–326CrossRefPubMedPubMedCentral

62.

Hammel P, Huguet F, van Laethem JL et al (2016) Effect of cemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA 315:1844–1853CrossRefPubMed

63.

Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413CrossRefPubMed

64.

Li D, Capanu M, Yu KH et al (2015) Treatment, Outcomes, and Clinical Trial Participation in Elderly Patients With Metastatic Pancreas Adenocarcinoma. Clin Colorectal Cancer 14:269–276e1CrossRefPubMedPubMedCentral

65.

Hackert T, Niesen W, Hinz U et al (2017) Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol 43:358–363CrossRefPubMed

66.

Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966CrossRefPubMed

67.

Wang-Gillam A, Li CP, Bodoky G et al (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387:545–557CrossRefPubMed

68.

Haas M, Siveke JT, Schenk M et al (2018) Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: a prospective phase II study of the ‚Arbeitsgemeinschaft Internistische Onkologie‘. Eur J Cancer 94:95–103CrossRefPubMed

69.

Sinn M, Bahra M, Liersch T et al (2017) CONKO-005: Adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial. J Clin Oncol 35:3330–3337CrossRefPubMed

70.

Vogel A, Kullmann F, Kunzmann V et al (2015) Patients with advanced pancreatic cancer and Hyperbilirubinaemia: review and German expert opinion on treatment with nab-Paclitaxel plus Gemcitabine. Oncol Res Treat 38:596–603CrossRefPubMed

71.

Rahma OE, Duffy A, Liewehr DJ et al (2013) Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol 24:1972–1979CrossRefPubMedPubMedCentral

72.

Portal A, Pernot S, Tougeron D et al (2015) Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. Br J Cancer 113:989–995CrossRefPubMedPubMedCentral

73.

Oettle H, Riess H, Stieler JM et al (2014) Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol 32:2423–2429CrossRefPubMed

74.

Pelzer U, Schwaner I, Stieler J et al (2011) Best supportive care (BSC) versus oxaliplatin, folinic acid and 5‑fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 47:1676–1681CrossRefPubMed

75.

Gill S, Ko YJ, Cripps C et al (2016) PANCREOX: a randomized phase III study of fluorouracil/Leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received Gemcitabine-based chemotherapy. J Clin Oncol 34:3914–3920CrossRefPubMed

76.

Hartung TJ, Brahler E, Faller H et al (2017) The risk of being depressed is significantly higher in cancer patients than in the general population: Prevalence and severity of depressive symptoms across major cancer types. Eur J Cancer 72:46–53CrossRefPubMed

77.

O’Donnell E (2013) The distress thermometer: a rapid and effective tool for the oncology social worker. Int J Health Care Qual Assur 26:353–359CrossRefPubMed

78.

Gotze H, Brahler E, Gansera L et al (2018) Anxiety, depression and quality of life in family caregivers of palliative cancer patients during home care and after the patient’s death. Eur J Cancer Care (engl) 27:e12606CrossRef

79.

Ter Veer E, van Rijssen LB, Besselink MG et al (2018) Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Lancet Oncol 19:e151–e160CrossRefPubMed

80.

Wolff RA (2018) Adjuvant or neoadjuvant therapy in the treatment in pancreatic malignancies: where are we? Surg Clin North Am 98:95–111CrossRefPubMed

81.

Mokdad AA, Minter RM, Zhu H et al (2017) Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol 35:515–522CrossRefPubMed

82.

Krantz BA, O’Reilly EM (2017) Biomarker based therapy in pancreatic ductal Adenocarcinoma: an emerging reality? Clin Cancer Res. https://doi.org/10.1158/1078-0432.CCR-16-3169 CrossRefPubMed

83.

Jameson GS, Borazanci EH, Babiker HM et al (2017) A phase Ib/II pilot trial with nab-paclitaxel plus gemcitabine plus cisplatin in patients (pts) with stage IV pancreatic cancer. J Clin Oncol 35:341–341CrossRef

84.

Jameson GS, Borazanci EH, Poplin E et al (2015) Abstract LB-003: High complete and partial response rate in a phase Ib pilot trial with cisplatin plus albumin-bound paclitaxel and gemcitabine in patients with advanced pancreatic cancer. Cancer Res 75:LB-3–LB-3CrossRef

85.

Teo MY, O’Reilly EM (2016) Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer? J Gastrointest Oncol 7:738–749CrossRefPubMedPubMedCentral

86.

Lemery S, Keegan P, Pazdur R (2017) First FDA approval agnostic of cancer site—when a biomarker defines the indication. N Engl J Med 377:1409–1412CrossRefPubMed

87.

Hu ZI, Shia J, Stadler ZK et al (2018) Evaluating mismatch repair deficiency in pancreatic adenocarcinoma: challenges and recommendations. Clin Cancer Res 24:1326–1336CrossRefPubMed

88.

Le DT, Durham JN, Smith KN et al (2017) Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science. https://doi.org/10.1126/science.aan6733 CrossRefPubMedPubMedCentral

89.

Hingorani SR, Zheng L, Bullock AJ et al (2018) HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. J Clin Oncol 36:359–366CrossRefPubMed

90.

Ramanathan RK, McDonough S, Philip PA et al (2018) A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313 (NCT #01959139). J Clin Oncol 36(suppl 4S):abstr 208

91.

Lowery MA, Jordan EJ, Basturk O et al (2017) Real-time genomic profiling of pancreatic ductal adenocarcinoma: potential actionability and correlation with clinical phenotype. Clin Cancer Res 23:6094–6100CrossRefPubMed

Titel: Duktales Adenokarzinom des Pankreas
verfasst von: Prof. Dr. E. Gallmeier
T. M. Gress
Publikationsdatum: 06.07.2018
Verlag: Springer Medizin
Schlagwörter: Pankreaskarzinom
Pankreaskarzinom
Erschienen in: Die Innere Medizin / Ausgabe 8/2018
Print ISSN: 2731-7080
Elektronische ISSN: 2731-7099
DOI: https://doi.org/10.1007/s00108-018-0460-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Duktales Adenokarzinom des Pankreas

Zusammenfassung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2018

Erratum zu: Thrombozytenaggregationshemmer bei koronarer, zerebraler und peripherer Makroangiopathie. Was, wann, wie lange?

Humangenetische Beratung und Testung bei erblich bedingten Herzerkrankungen

Mitteilungen des BDI

Kortikoide bei Patienten im septischen Schock: Hilfreich oder nicht?

Humangenetik beim atypischen hämolytisch-urämischen Syndrom – Rolle in Diagnostik und Therapie

Seltene Erkrankungen: vom Symptom zur Diagnose mit moderner Softwareunterstützung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin